RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

Commentaries on Twitter

Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19.

People on MV (n=386) randomized to vilobelimab vs placebo. Mortality was (maybe) reduced in a subgroup w/ more severe illness…?https://t.co/bO5XiRptag
1/ pic.twitter.com/EUNda67T9j

— Nick Mark MD (@nickmmark) September 11, 2022

NEW Research—In addition to SOC, vilobelimab improves survival of invasive mechanically ventilated patients w/ #COVID19 and leads to a significant decrease in mortality

Read the PANAMO study from Prof Alexander Vlaar & colleagues here https://t.co/k5UuqQtqyE pic.twitter.com/Xmrb76ZpzW

— The Lancet Respiratory Medicine (@LancetRespirMed) September 8, 2022